Pharmacia Limited

Ramsgate Road, Sandwich, Kent, CT13 9NJ
Telephone: +44 (0)1304 616 161
Fax: +44 (0)1304 656 221

Summary of Product Characteristics last updated on the eMC: 23/02/2011
SPC Cyklokapron Injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/02/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   01-Jul-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.2 (Posology and method of administration) – Paediatric prescribing information has been added/updated.
Section 4.3 (Contraindications) – Contraindications have been added.
Section 4.4 (Special warnings and precautions for use) – Warnings have been added/updated.
Section 4.8 (Undesirable effects) – Undesirable effects have been added and ordered by system/organ class.
Section 5.1 (Pharmacodynamic properties) – Paediatric information has been added.
Section 5.2 (Pharmacokinetic properties)
Updated on 23/10/2009 and displayed until 23/02/2011
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   01-Jul-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 4.8 has been revised to include the following information: ‘Nervous System Disorders: dizziness, convulsions’

Updated on 15/01/2008 and displayed until 23/10/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 19/12/2007 and displayed until 15/01/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 7: Revision of MAH address to the following:

 

Pharmacia Ireland Ltd.,

9 Riverwalk

National Digital Park

Citywest Business Campus

Dublin 24

Updated on 23/10/2007 and displayed until 19/12/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.4 – Change from Plasminogen to fibrinolysin

 

Section 5.1 – Change from Plasminogen to fibrinolysin

 

Section 7 – MA Holder address amended from Milton Keynes to Sandwich

Updated on 04/09/2007 and displayed until 23/10/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 6.2 - Incompatibilities
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.4 – Change from Plasminogen to fibrinolysin

 

Section 5.1 – Change from Plasminogen to fibrinolysin

 

Section 6.2 – Change from Plasminogen to fibrinolysin

Updated on 10/08/2007 and displayed until 04/09/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   07/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.4 – Change from Plasminogen to fibrinolysin

 

Section 5.1 – Change from Plasminogen to fibrinolysin

 

Section 7 – MA Holder address amended from Milton Keynes to Sandwich

Updated on 11/12/2001 and displayed until 10/08/2007
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
  • Correction of spelling/typing errors
Updated on 11/12/2001 and displayed until 11/12/2001
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 13/07/2001 and displayed until 11/12/2001
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 06/09/1999 and displayed until 13/07/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   tranexamic acid